Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
Rhea-AI Summary
Pacira (Nasdaq: PCRX) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026.
Following the release, Pacira will host a live conference call and webcast at 4:30 p.m. ET; telephone participants must pre-register to receive dial-in information and a PIN. A webcast replay will be available on the company website for about two weeks.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PCRX
On the day this news was published, PCRX gained 1.84%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PCRX was down 1.35% while peers were mixed: COLL -1.66%, AMPH +1.40%, HROW +2.08%. Momentum scanner flagged 2 peers (e.g., HROW up 4.38%), suggesting stock-specific factors rather than a broad sector move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date set | Neutral | +1.5% | Announced timing of Q4 and full-year 2025 results and earnings call. |
Limited tag-specific history: the last earnings-date announcement saw a modest positive move of 1.49% the next day.
Recent Pacira news has focused on clinical and strategic developments, while the only prior earnings date item in the last six months announced 2025 results timing on Feb 26, 2026 and coincided with a 1.49% next-day gain. Today’s first-quarter 2026 reporting date on Apr 30, 2026 fits that pattern of neutral scheduling updates that have historically prompted only modest share-price reactions.
Historical Comparison
Past earnings-date news for PCRX led to an average move of 1.49%. Today’s first-quarter 2026 reporting schedule appears consistent with prior neutral timing announcements.
Earnings-date communications progressed from announcing 2025 full-year results timing to scheduling first-quarter 2026 results, maintaining a similar call format and disclosure approach.
Market Pulse Summary
This announcement sets the timing for Pacira’s first-quarter 2026 results on April 30, 2026, with a conference call at 4:30 p.m. ET and a replay available for about two weeks. A prior earnings-date notice was followed by a modest 1.49% move, suggesting such updates have been routine. Investors may focus on the upcoming figures, guidance, and any commentary on strategy and costs when results are released.
AI-generated analysis. Not financial advice.
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com